Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset
Scientists at deCODE genetics, a subsidiary of Amgen, have together with their Nordic collaborators published the largest genome-wide association study to date on rheumatoid arthritis (RA) in Annals of the Rheumatic Diseases, including over thirty thousand cases and one million controls.
DeCODE genetics publishes the largest ever study of the plasma proteome
In a study published in Nature genetics, scientists at deCODE genetics demonstrate how measuring the levels of a large number of proteins in plasma at population scale when combined with data on sequence diversity and RNA expression dramatically increases insights into human diseases and other phenotypes.
New study on inheritance and fetal growth
Scientists from deCODE genetics have mapped 243 sequence variants affecting fetal growth, separating maternal genome and fetal genome. It sheds light on the relationships between hypertension, diabetes and fetal growth
New biomarker for osteoarthritis
Scientists at deCODE genetics have found a new biomarker for osteoarthritis, that outperforms previously reported biomarkers and is an independent predictor of disease.
UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.